Education
About Us
Working with TipRanks
Follow Us
Senti Biosciences (SNTI)
NASDAQ:SNTI
SNTI Analyst Ratings
Moderate Buy
2 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
SNTI Stock 12 Month Forecast
Average Price Target
$12.00
▲(581.82% Upside)
| Highest Price Target$12.00 | Average Price Target$12.00 | Lowest Price Target$12.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Leerink Partners
$6
Buy
240.91%
Upside
Initiated
11/21/25
We are initiating coverage of Senti Bio (SNTI) with an Outperform rating and a $6 PT. Senti’s novel Logic- Gated gene circuit platform offers a promising solution to solve the therapeutic window problem that has plagued cell therapies pursuing cancers with “dirty” antigen targets. Senti’s lead clinical candidate, SENTI-202, is an elegantly designed allogeneic, or off-the-shelf, CAR-NK cell therapy in Ph 1 for relapsed or refractory (r/r) acute myeloid leukemia (AML)—a notoriously treatment-refractory malignancy that has proven a development graveyard due to dirtier targets all expressed by normal hematopoietic stem cells, profoundly heterogeneous and immunosuppressive nature, and a frail patient population.
H.C. Wainwright
$12
Buy
581.82%
Upside
Reiterated
11/14/25
Promising Outlook for Senti Biosciences' SENTI-202: Positive Phase 1 Results and Innovative CAR-NK Technology Justify Buy RatingValuation and Risks. Our Buy rating and $12 price target are based on a discounted cash flow analysis (DCF). In our DCF, we extend our estimates to 2040 and assign a 12% discount rate and 2% terminal value, given that we view Senti's technology as a platform. We currently assume value for SENTI-202 for the treatment of r/r AML with 20% POS and and have not included other pipeline assets or indications in our valuation.
Chardan Capital
$12
Buy
581.82%
Upside
Reiterated
11/13/25
Laidlaw
$5
Buy
184.09%
Upside
Initiated
06/06/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Leerink Partners
$6
Buy
240.91%
Upside
Initiated
11/21/25
We are initiating coverage of Senti Bio (SNTI) with an Outperform rating and a $6 PT. Senti’s novel Logic- Gated gene circuit platform offers a promising solution to solve the therapeutic window problem that has plagued cell therapies pursuing cancers with “dirty” antigen targets. Senti’s lead clinical candidate, SENTI-202, is an elegantly designed allogeneic, or off-the-shelf, CAR-NK cell therapy in Ph 1 for relapsed or refractory (r/r) acute myeloid leukemia (AML)—a notoriously treatment-refractory malignancy that has proven a development graveyard due to dirtier targets all expressed by normal hematopoietic stem cells, profoundly heterogeneous and immunosuppressive nature, and a frail patient population.
H.C. Wainwright
$12
Buy
581.82%
Upside
Reiterated
11/14/25
Promising Outlook for Senti Biosciences' SENTI-202: Positive Phase 1 Results and Innovative CAR-NK Technology Justify Buy RatingValuation and Risks. Our Buy rating and $12 price target are based on a discounted cash flow analysis (DCF). In our DCF, we extend our estimates to 2040 and assign a 12% discount rate and 2% terminal value, given that we view Senti's technology as a platform. We currently assume value for SENTI-202 for the treatment of r/r AML with 20% POS and and have not included other pipeline assets or indications in our valuation.
Chardan Capital
$12
Buy
581.82%
Upside
Reiterated
11/13/25
Laidlaw
$5
Buy
184.09%
Upside
Initiated
06/06/25
Best Analysts Covering Senti Biosciences
1 Month
xxx
Success Rate
3/10 ratings generated profit
Average Return
+8.30%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 30.00% of your transactions generating a profit, with an average return of +8.30% per trade.
3 Months
xxx
Success Rate
2/10 ratings generated profit
Average Return
-11.45%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 20.00% of your transactions generating a profit, with an average return of -11.45% per trade.
1 Year
Success Rate
1/10 ratings generated profit
Average Return
-48.03%
reiterated a buy rating 9 days ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 10.00% of your transactions generating a profit, with an average return of -48.03% per trade.
2 Years
xxx
Success Rate
1/10 ratings generated profit
Average Return
-51.15%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 10.00% of your transactions generating a profit, with an average return of -51.15% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
SNTI Analyst Recommendation Trends
Rating
May 25
Jun 25
Aug 25
Oct 25
Nov 25
Strong Buy
1
1
2
2
4
Buy
0
1
1
1
0
Hold
4
3
0
0
0
Sell
1
1
0
0
0
Strong Sell
0
0
0
0
0
total
6
6
3
3
4
Each month's total comprises the sum of three months' worth of ratings.
SNTI Financial Forecast
SNTI Stock Forecast FAQ
What is SNTI’s average 12-month price target, according to analysts?
Based on analyst ratings, Senti Biosciences’s 12-month average price target is 12.00.
What is SNTI’s upside potential, based on the analysts’ average price target?
Senti Biosciences has 581.82% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is SNTI a Buy, Sell or Hold?
Senti Biosciences has a consensus rating of Moderate Buy which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
What is Senti Biosciences’s price target?
The average price target for Senti Biosciences is 12.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $12.00 ,the lowest forecast is $12.00. The average price target represents 581.82% Increase from the current price of $1.76.
The highest analyst price target is $12.00 ,the lowest forecast is $12.00. The average price target represents 581.82% Increase from the current price of $1.76.
What do analysts say about Senti Biosciences?
Senti Biosciences’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
How can I buy shares of SNTI?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.